Best Safest Stocks To Watch For 2019


Safestore Holdings Plc (LON:SAFE)’s share price reached a new 52-week high during trading on Wednesday . The company traded as high as GBX 554 ($7.43) and last traded at GBX 554 ($7.43), with a volume of 525524 shares. The stock had previously closed at GBX 554 ($7.43).

Several equities analysts recently issued reports on the company. Peel Hunt restated a “hold” rating on shares of Safestore in a research note on Thursday, April 5th. Numis Securities restated an “add” rating and set a GBX 570 ($7.65) price target on shares of Safestore in a research note on Thursday, February 22nd. Finally, Liberum Capital restated a “buy” rating and set a GBX 560 ($7.51) price target on shares of Safestore in a research note on Thursday, February 22nd. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Safestore presently has an average rating of “Buy” and a consensus price target of GBX 515.83 ($6.92).

Best Safest Stocks To Watch For 2019: Genfit SA (GNFTF)


Advisors’ Opinion:

  • [By ]

    This phase 2 data for Madrigal was phenomenal, which is why I think it will do well in a phase 3 trial. The other side of the trade is that Intercept Pharmaceuticals (ICPT) and Genfit (OTCPK:GNFTF) are further along with phase 3 trials, which are expected to read out NASH results by 2019/2020. Intercept has a good drug with Ocaliva, however, it suffers from toxicity issues when Doctors prescribe higher than necessary dosing. On the flip side, Ocaliva has shown a greater difference in fibrosis reduction for NASH in its phase 2 FLINT trial compared to MGL-3196. What do I mean by that? Well, as you can see above MGL-3196 obtained a fibrosis reduction in NASH patients of 29% compared to 23% for those on placebo creating a difference of only 6%. If you look at Ocaliva from the FLINT trial, from Intercept Pharmaceuticals, it had a fibrosis reduction of 35% compared to 19% of those NASH patients on placebo. It is just something to keep in mind. I still believe that MGL-3196 will eventually be approved. The question that should be asked is how well will it do compared to other competitors in the same space with better fibrosis reductions? That will be key, because NASH causes fibrosis (scarring) of the liver. Fibrosis eventually turns into cirrhosis of the liver, which can eventually lead to liver failure. That’s why, in my opinion, a drug that will have the most impact on NASH will be one that shows a major reduction in fibrosis. The good news is that the NASH market is expected to reach between $20 to $30 billion in the coming years. It is a large market for plenty of players in this space. The other endpoints are important as well, but in a competitive market such as NASH, fibrosis reduction will make the difference in terms of more sales. This is just an important factor to keep in mind.

  • [By ]

    Heres what we wrote: With GR-MD-02, Galectin is also targeting a different spectrum of NASH. The companys programs with GR-MD-02 are focusing on NASH treatment in individuals with advanced fibrosis and cirrhosis. As we mentioned before, Genfit (OTCPK:GNFTF) and Intercept (ICPT) are targeting what can be termed as the sweet spot of the NASH spectrum. Galecctin is one of the few companies targeting advanced stage of the disease. This makes it both an interesting and at the same time risky bet in the NASH space.

  • [By SEEKINGALPHA.COM]

    In a recent article, we discussed what makes Genfits (OTCPK:GNFTF) Elafibranor one of the most promising candidates in the NASH treatment development space. Given the unmet need (no approved therapies), Elafibranors mechanism of action and the potential it has shown in clinical stages, we see a strong chance of approval if the pivotal Phase 3 study succeeds. In this article, we will briefly discuss the chances of Elafibranors success in clinical stages and Genfits valuation based on the potential of its lead product candidate. We will briefly also discuss the risks to the investment thesis.

Best Safest Stocks To Watch For 2019: AcelRx Pharmaceuticals Inc.(ACRX)


Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Comstock Holding Companies, Inc. (NASDAQ: CHCI) shares climbed 154.95 percent to close at $5.15 on Thursday. Comstock reported conversion of the majority of its unsecured, short-term debt into non-convertible preferred equity.
    Tyme Technologies, Inc. (NASDAQ: TYME) jumped 33.45 percent to close at $3.87.
    Universal Corporation (NYSE: UVV) gained 29.72 percent to close at $62.85 after reporting fiscal Q4 results.
    Evolus, Inc. (NASDAQ: EOLS) shares rose 22.93 percent to close at $23.80.
    nLIGHT, Inc. (NASDAQ: LASR) jumped 21.52 percent to close at $36.37 following Q1 results.
    Hudson Technologies Inc. (NASDAQ: HDSN) gained 20.28 percent to close at $2.61.
    The Cato Corporation (NYSE: CATO) shares rose 19.57 percent to close at $21.45 after the company posted better-than-expected first-quarter results.
    AXT, Inc. (NASDAQ: AXTI) gained 18.8 percent to close at $7.90.
    Catasys, Inc. (NASDAQ: CATS) rose 16.33 percent to close at $6.41.
    HUYA Inc. (NYSE: HUYA) rose 15.68 percent to close at $23.09 on Thursday.
    Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) climbed 15.11 percent to close at $6.02 on Thursday after gaining 6.30 percent on Wednesday. Baird initiated coverage on Marinus Pharmaceuticals with an Outperform rating.
    Destination Maternity Corporation (NASDAQ: DEST) shares rose 14.48 percent to close at $3.32 after the board announced late Wednesday the election of four activist-backed director nominees. Three women and one man comprise the selected group championed by NGM Capital’s Nathan Miller and Kenosis Capital’s Peter O’Malley. Destination Maternity had advocated for another slate of three men and interim CEO Melissa Payner-Gregor. The new directors are Holly Alden, Marla Ryan, Anne-Charlotte Windal and Christopher Morgan.
    China Rapid Finance Limited (NYSE: XRF) gained 11.53 percent to close at $3.29 after announcing preliminary Q1 results.
    Bilibili Inc.. (NASDAQ: BILI) shares rose 11.33 pe
  • [By Lisa Levin] Gainers
    Stellar Biotechnologies, Inc. (NASDAQ: SBOT) rose 32 percent to $2.89 in pre-market trading after the company disclosed that it achieved robust viral clearance for its manufacturing process.
    Babcock & Wilcox Enterprises, Inc. (NYSE: BW) rose 17.7 percent to $3.03 in pre-market trading after an amended 13D filing from Steel Partners Holdings shows a raised stake in the company from 6.99 million shares to 29.98 million shares, or a 17.8 percent stake.
    AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) shares rose 12.7 percent to $3.55 in pre-market trading after the company announced the FDA acceptance of NDA for DSUVIA.
    Williams-Sonoma, Inc. (NYSE: WSM) shares rose 11.7 percent to $54.95 in pre-market trading. after the company reported stronger-than-expected results for its first quarter. The company also raised its FY18 earnings and sales guidance.
    Bilibili Inc. (NASDAQ: BILI) shares rose 9.3 percent to $13.59 in pre-market trading after announcing Q1 results.
    Stein Mart, Inc. (NASDAQ: SMRT) rose 8.1 percent to $3.46 in pre-market trading after reporting strong Q1 earnings.
    Universal Corporation (NYSE: UVV) rose 8.1 percent to $52.35 in pre-market trading after reporting fiscal Q4 results.
    Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) rose 8.1 percent to $5.65 in pre-market trading after gaining 6.30 percent on Wednesday.
    CEL-SCI Corporation (NYSE: CVM) rose 6.1 percent to $3.30 in pre-market trading after climbing 9.51 percent on Wednesday.
    TransEnterix, Inc. (NYSE: TRXC) rose 6 percent to $3.10 in pre-market trading after reporting a loan deal for $40 million in term loans with Hercules Capital.
    Stage Stores, Inc. (NYSE: SSI) rose 5.6 percent to $3.40 in pre-market trading following Q1 results.
    Koss Corporation (NASDAQ: KOSS) shares rose 5.2 percent to $2.42 in the pre-market trading session after falling 2.54 percent on Wednesday.


     

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Cemtrex, Inc. (NASDAQ: CETX) fell 7.1 percent to $2.10 in pre-market trading after rising 4.15 percent on Friday
    Bioblast Pharma Ltd. (NASDAQ: ORPN) fell 7.1 percent to $2.10 in pre-market trading after dipping 9.05 percent on Friday.
    LexinFintech Holdings Ltd. (NASDAQ: LX) fell 5.9 percent to $17.15 in pre-market trading after reporting Q1 results.
    AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) shares fell 5.1 percent to $2.80 in pre-market trading after dropping 1.67 percent on Friday.
    China Telecom Corporation Limited (NYSE: CHA) shares fell 4.1 percent to $45.70 in pre-market trading.
    Carver Bancorp, Inc. (NASDAQ: CARV) fell 4 percent to $8.00 in pre-market trading after tumbling 24.36 percent on Friday.
    Tuesday Morning Corporation (NASDAQ: TUES) shares fell 3.6 percent to $2.65 in pre-market trading.
    Cheetah Mobile Inc. (NYSE: CMCM) shares fell 3.4 percent to $11.90 in pre-market trading following Q1 results.
    Qudian Inc. (NYSE: QD) fell 3.3 percent to $11.10 in pre-market trading after reporting Q1 results.
    Fifth Third Bancorp (NASDAQ: FITB) fell 3.1 percent to $32.53 in pre-market trading after announcing plan to acquire MB Financial for $54.70 per share in cash and stock

  • [By Lisa Levin] Gainers
    Comstock Holding Companies, Inc. (NASDAQ: CHCI) shares surged 115.8 percent to $4.3591. Comstock reported conversion of the majority of its unsecured, short-term debt into non-convertible preferred equity.
    Stellar Biotechnologies, Inc. (NASDAQ: SBOT) jumped 38.2 percent to $3.0251 after the company disclosed that it achieved robust viral clearance for its manufacturing process.
    Universal Corporation (NYSE: UVV) surged 26.7 percent to $61.40 after reporting fiscal Q4 results.
    Hudson Technologies Inc. (NASDAQ: HDSN) rose 18.9 percent to $2.58.
    Evolus, Inc. (NASDAQ: EOLS) shares gained 17.8 percent to $22.8009.
    The Cato Corporation (NYSE: CATO) shares gained 17.5 percent to $21.07 after the company posted better-than-expected first-quarter results.
    Tyme Technologies, Inc. (NASDAQ: TYME) rose 15.9 percent to $3.3613.
    Destination Maternity Corporation (NASDAQ: DEST) shares gained 15.5 percent to $3.35 after the board announced late Wednesday the election of four activist-backed director nominees. Three women and one man comprise the selected group championed by NGM Capital’s Nathan Miller and Kenosis Capital’s Peter O’Malley. Destination Maternity had advocated for another slate of three men and interim CEO Melissa Payner-Gregor. The new directors are Holly Alden, Marla Ryan, Anne-Charlotte Windal and Christopher Morgan.
    AXT, Inc. (NASDAQ: AXTI) rose 15 percent to $7.65.
    nLIGHT, Inc. (NASDAQ: LASR) gained 14.5 percent to $34.27 following Q1 results.
    Achieve Life Sciences, Inc. (NASDAQ: ACHV) rose 14.3 percent to $11.4303.
    Bilibili Inc.. (NASDAQ: BILI) shares climbed 13.9 percent to $14.16 after announcing Q1 results.
    Babcock & Wilcox Enterprises, Inc. (NYSE: BW) gained 13.2 percent to $2.91 after an amended 13D filing from Steel Partners Holdings shows a raised stake in the company from 6.99 million shares to 29.98 million shares, or a 17.8 percent stake.
    HUYA Inc. (NYSE: HUYA) gained 13.1
  • [By Shane Hupp]

    Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Safest Stocks To Watch For 2019: BlackRock Strategic Municipal Trust Inc. (BSD)

Advisors’ Opinion:

  • [By Ethan Ryder]

    BitSend (CURRENCY:BSD) traded down 8.9% against the U.S. dollar during the 1 day period ending at 16:00 PM Eastern on June 20th. During the last week, BitSend has traded 5.1% higher against the U.S. dollar. BitSend has a market cap of $6.58 million and approximately $147,698.00 worth of BitSend was traded on exchanges in the last 24 hours. One BitSend coin can now be purchased for approximately $0.34 or 0.00004993 BTC on major exchanges including LiteBit.eu, Cryptopia, SouthXchange and Bittrex.

  • [By Logan Wallace]

    BitSend (CURRENCY:BSD) traded 3.6% higher against the U.S. dollar during the one day period ending at 21:00 PM Eastern on June 2nd. One BitSend coin can currently be bought for approximately $0.53 or 0.00006976 BTC on popular cryptocurrency exchanges including Livecoin, Cryptopia, SouthXchange and LiteBit.eu. BitSend has a market cap of $10.33 million and approximately $22,076.00 worth of BitSend was traded on exchanges in the last 24 hours. In the last seven days, BitSend has traded up 2.3% against the U.S. dollar.

  • [By Ethan Ryder]

    BitSend (BSD) is a PoW/PoS coin that uses the X11 hashing algorithm. BitSend’s total supply is 19,754,725 coins. BitSend’s official Twitter account is @Bit_send. The official website for BitSend is www.bitsend.info.

Best Safest Stocks To Watch For 2019: Arch Coal, Inc. (ARCH)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Scopus Asset Management L.P. lowered its stake in shares of Arch Coal Inc (NYSE:ARCH) by 83.7% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 20,400 shares of the energy company’s stock after selling 104,600 shares during the quarter. Scopus Asset Management L.P.’s holdings in Arch Coal were worth $1,874,000 as of its most recent SEC filing.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Arch Coal (ARCH)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Arch Coal (NYSE:ARCH) had its target price upped by B. Riley from $95.00 to $96.00 in a report released on Wednesday morning. B. Riley currently has a buy rating on the energy company’s stock. B. Riley also issued estimates for Arch Coal’s Q3 2018 earnings at $3.14 EPS and Q4 2018 earnings at $2.20 EPS.

  • [By Stephan Byrd]

    Arch Coal (NYSE: ARCH) and Contura Energy (OTCMKTS:CNTE) are both small-cap basic materials companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.

Best Safest Stocks To Watch For 2019: Finisar Corporation(FNSR)

Advisors’ Opinion:

  • [By Harsh Chauhan]

    Apple is the more immediate catalyst for Lumentum as it is currently the biggest buyer of VCSEL arrays on the market. It is estimated that Apple now supplies40% of the chipmaker’s top line as compared to none at the beginning of 2017. This is because Lumentum became Apple’s sole supplier thanks to a reported inability of rival Finisar (NASDAQ:FNSR) to meetCupertino’s specifications last year. But the iPhone maker didn’t want to put all its eggs in one basket.

  • [By Ethan Ryder]

    Finisar (NASDAQ:FNSR) Director Jerry S. Rawls sold 30,208 shares of the stock in a transaction dated Tuesday, May 1st. The stock was sold at an average price of $15.59, for a total transaction of $470,942.72. Following the transaction, the director now directly owns 593,466 shares of the company’s stock, valued at $9,252,134.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Finisar (FNSR)


    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    News coverage about Finisar (NASDAQ:FNSR) has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Finisar earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media stories about the technology company an impact score of 48.3712393394037 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

  • [By Leo Sun]

    That buyout was considered a major blow to Finisar (NASDAQ:FNSR), which wasalso reportedly mulling a bid for Oclaro. I’m not saying Finisar will buy Acacia, but the latter’s enterprise value of $740 million makes it a feasible takeover target for bigger fiber players.

  • [By Lisa Levin] Gainers
    Acacia Communications, Inc. (NASDAQ: ACIA) shares rose 18.3 percent to $37.25 in pre-market trading after gaining 1.74 percent on Friday.
    Kitov Pharma Ltd (NASDAQ: KTOV) rose 12.1 percent to $2.69 in pre-market trading after surging 4.80 percent on Friday.
    NXP Semiconductors N.V. (NASDAQ: NXPI) rose 10.9 percent to $109.75 in pre-market trading after Bloomberg reported that the China’s Commerce Ministry has restarted its review of QUALCOMM Incorporated’s (NASDAQ: QCOM) proposed takeover of NXP Semiconductors.
    Renewable Energy Group, Inc. (NASDAQ: REGI) rose 10.6 percent to $15.20 in pre-market trading. Renewable Energy will replace Synchronoss Technologies Inc. (NASDAQ: SNCR) in the S&P SmallCap 600 on Tuesday, May 15.
    NeoPhotonics Corporation (NYSE: NPTN) rose 10 percent to $6.40 in pre-market trading.
    Vaxart, Inc. (NASDAQ: VXRT) shares rose 8 percent to $5.54 in pre-market trading after gaining 2.19 percent on Friday.
    Profire Energy, Inc. (NASDAQ: PFIE) rose 7.3 percent to $4.58 in pre-market trading after gaining 6.22 percent on Friday.
    Marvell Technology Group Ltd. (NASDAQ: MRVL) rose 7 percent to $22.49 in pre-market trading after falling 1.96 percent on Friday.
    Oclaro, Inc. (NASDAQ: OCLR) shares rose 6.9 percent to $9.16 in pre-market trading.
    TransEnterix, Inc. (NYSE: TRXC) rose 5.7 percent to $2.24 in pre-market trading after gaining 3.92 percent on Friday.
    CVR Refining, LP (NYSE: CVRR) rose 5.4 percent to $19.70 in pre-market trading.
    Federal Agricultural Mortgage Corporation (NYSE: AGM) rose 5.2 percent to $92.95 in pre-market trading.
    International Game Technology PLC (NYSE: IGT) rose 5.2 percent to $29.94 in pre-market trading.
    Lumentum Holdings Inc. (NASDAQ: LITE) shares rose 5.1 percent to $66.30 in the pre-market trading session.
    Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) shares rose 5 percent to $10.70 in pre-market trading after climbing 15.66 percent on Friday.
    Finisar

Leave a Reply

Your email address will not be published. Required fields are marked *